Verona Pharma plc (VRNA): A Bull Case Theory [Yahoo! Finance]
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Yahoo! Finance
Verona Pharma plc (VRNA)'s share was trading at $67.50 as of March 4 th . VRNA's forward P/E was 434.78 according to Yahoo Finance. A scientist working in a laboratory performing tests on a newly developed biotechnology drug. Verona Pharma (VRNA) has reported strong Q4 earnings, reinforcing the bullish case for its long-term growth. CEO Mark Hahn indicated that sales could approach $300 million in 2025, though the company refrained from issuing formal guidance. However, management did not contest the consensus estimate of $270 million and hinted at exceeding it. The company's lead product, Ohtuvayre, is emerging as a market mainstay, with growing adoption and refills expected to drive recurring revenue, mirroring the success of Trelegy, where 90% of sales come from refills. Verona estimates that capturing just 5-10% of the U.S. market could generate $5.5B-$11B in annual sales, with each 1% share equating to $1.1B in revenue. The company is progressing in its expansion, with Phase
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $100.00 price target on the stock.MarketBeat
- Verona Pharma plc (VRNA)'s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend [Yahoo! Finance]Yahoo! Finance
- BioSpace Announces Inaugural 40 Under 40 WinnersPR Newswire
- Merck acquisition of Verona Pharma approved by court [Seeking Alpha]Seeking Alpha
- Acquisition of Verona by MSD Approved by the High Court of Justice of England and WalesGlobeNewswire
VRNA
Analyst Actions
- 10/8/25 - Cantor Fitzgerald
VRNA
Sec Filings
- 10/7/25 - Form S-8
- 10/7/25 - Form S-8
- 10/7/25 - Form S-8
- VRNA's page on the SEC website